drugset / Trial / NCT05389293
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Timeline
- Start
- 2022-05-27
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mosunetuzumab | Monoclonal antibody | 45 mg | Subcutaneous |
| Subject | Zanubrutinib | Small molecule | — | — |